Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333117 | 0.92 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH4KDM4E | |
| SCHEMBL7549813 | 0.82 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH4AOC3 | |
| SCHEMBL7355775 | 0.79 | LOXL2 (0.59) | LOXL2MTNR1AMTNR1BHRH4KDM4E | |
| SCHEMBL2185508 | 0.79 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH4AOC3 | |
| SCHEMBL653529 | 0.79 | LOXL2 (0.63) | LOXL2MTNR1AMTNR1BHRH4KDM4E | |
| SCHEMBL5642064 | 0.77 | LOXL2 (0.60) | LOXL2MTNR1AMTNR1BHRH4AOC3 | |
| SCHEMBL6156791 | 0.76 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH4AOC3 | |
| SCHEMBL5586763 | 0.76 | LOXL2 (0.55) | LOXL2MTNR1AMTNR1BHRH4AOC3 | |
| SCHEMBL1327113 | 0.75 | LOXL2 (0.58) | LOXL2MTNR1AMTNR1BHRH4KDM4E | |
| SCHEMBL7551798 | 0.74 | MTNR1A (0.55) | LOXL2MTNR1AMTNR1BHRH4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620824-B2 | Process for the synthesis of gonadotropin releasing hormone antagonists | MERCK & CO., INC. | 2003-09-16 | — | — | US | disclosed |
| EP-1095038-B1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030013876-A1 | Process for the synthesis of gonadotropin releasing hormone antagonists | MERCK & CO., INC. | 2003-01-16 | — | — | US | disclosed |
| EP-1067930-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1171135-A4 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1161431-A4 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1165075-A4 | 6-AZAINDOLE COMPOUNDS AS ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1049472-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1027046-A4 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-0873336-B1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO INC (US) | 2002-03-27 | — | — | EP | disclosed |
| EP-0882040-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| EP-0873336-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (a New Jersey corp.) (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0868178-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-07 | — | — | EP | disclosed |
| US-5780437-A | ADMINISTERING TO TREAT SEX-HORMONE RELATED DISORDERS | MERCK & CO., INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5756507-A | TREATING SEX HORMONE RELATED DISORDERS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1997021707-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021704-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021435-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013876-A1 | Process for the synthesis of gonadotropin releasing hormone antagonists | GNRHR, FSHR, GHRHR | LOXL2 4595/4885MTNR1A 185/4885MTNR1B 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.